Einhorn L H
University Hospital, Indianapolis, IN 46202-5265.
Cancer. 1993 May 15;71(10):3182-4. doi: 10.1002/1097-0142(19930515)71:10<3182::aid-cncr2820711046>3.0.co;2-o.
Testicular cancer has become a model for a curable neoplasm. Our studies with cisplatin combination chemotherapy allow us to conclude that (1) short-duration intensive induction therapy with the most active agents in optimal dosage is more important than maintenance therapy; (2) modest dose escalation increases toxicity without improving therapeutic efficacy; (3) it is possible to develop curative salvage therapy for refractory germ cell tumors; and (4) preclinical models predicting synergism, such as vinblastine+bleomycin or cisplatin+VP-16, have clinical relevance. Finally, testicular cancer also has become a model for new drug development. Cisplatin was approved by the FDA for testis and ovarian cancer and VP-16 and ifosfamide for refractory germ cell tumors. The success of these studies confirms the importance of the continued search for new investigational drugs in all solid tumors.
睾丸癌已成为可治愈肿瘤的一个典范。我们对顺铂联合化疗的研究使我们能够得出以下结论：（1）使用最有效的药物以最佳剂量进行短期强化诱导治疗比维持治疗更重要；（2）适度增加剂量会增加毒性而不会提高治疗效果；（3）有可能为难治性生殖细胞肿瘤开发治愈性挽救疗法；（4）预测协同作用的临床前模型，如长春花碱+博来霉素或顺铂+依托泊苷，具有临床相关性。最后，睾丸癌也已成为新药开发的一个典范。顺铂被美国食品药品监督管理局批准用于睾丸癌和卵巢癌，依托泊苷和异环磷酰胺用于难治性生殖细胞肿瘤。这些研究的成功证实了在所有实体瘤中持续寻找新的研究性药物的重要性。
